Abstract
A comparative randomised open study was carried out in 120 patients uncle undergoing cerebral angiography, to compare two low-osmolar contrast media (LOCM). All the patients participated voluntarily in the trial. Half the patients (n = 60) received sodium and meglumine ioxaglate (Hexabrix 320) and the other half (n = 60) iohexol (Omnipaque 300). Contrast agent efficacy was evaluated at the different cerebral levels explored. Adverse reactions were recorded immediately and 24 h post-administration. Diagnostic quality was considered excellent in 95% of cases with Omnipaque and in 97% of cases with Hexabrix. Image quality was excellent in 95%, of cases with Omnipaque and in 100 % of cases with Hexabrix. In terms of both efficacy and safety, no significant difference was observed between the agents. Thus, low osmolality would appear to be the essential factor in this indication as far as safety is concerned. No significant difference in safety was noted between the ionic LOCM Hexabrix and the non-ionic LOCM Omnipaque.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
